

EXHIBIT A

EXHIBIT A: PENDING CLAIMS

What is claimed is:

1. (Original) A method of treating or prophylaxis of a disorder ameliorated by the inhibition of serotonin reuptake at 5-HT₂ receptors and/or the inhibition of dopamine reuptake at dopamine D₂ receptors in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of a ziprasidone metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.
2. (Currently Amended) The method of claim 1 wherein the disorder is ~~selected from the group consisting of~~ a neuroleptic disorders, a migraines, acute intermittent porphyria, intractable hiccups, Parkinson's disease ~~and~~ or epilepsy.
3. (Original) A method of treating or prophylaxis of a neuroleptic disorder in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of a ziprasidone metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.
4. (Original) The method of claim 1 or 3 wherein the patient is a human.
5. (Previously Amended) The method of claim 1 wherein the ziprasidone metabolite is ziprasidone sulfoxide or ziprasidone sulfone.
6. (Currently Amended) The method of claim 3 wherein the neuroleptic disorder is ~~selected from the group consisting of~~ psychosis, an affective disorders, ~~and~~ or anxiety.
7. (Currently Amended) The method of claim 6 wherein the psychosis is ~~selected from the group consisting of~~ schizophrenia, schizo-affective psychosis, hallucinations, paranoia, affective psychosis, alcoholic psychoses, arteriosclerotic psychosis, amnesic psychosis, bipolar psychosis, Cheyne-Stokes psychosis, climacteric psychosis, depressive psychosis, drug psychosis, dysmnestic psychosis, hysterical psychosis,

infection-exhaustion psychosis, Korsakoff's psychosis, postinfectious psychosis, postpartum psychosis, posttraumatic psychosis, senile psychosis, situational psychosis, toxic psychosis, traumatic psychosis, ~~and~~ or Windigo psychosis.

8. (Currently Amended) The method of claim 6 wherein the affective disorder is ~~selected from the group consisting of~~ depression, attention deficit disorder, attention deficit disorder with hyperactivity, bipolar conditions ~~and~~ or manic conditions.

9. (Currently Amended) The method of claim 6 wherein the anxiety is ~~selected from the group consisting of~~ anxiety attacks, free-floating anxiety, noetic anxiety, separation anxiety, ~~and~~ or situation anxiety.

10. (Original) The method of claim 1 or 3 wherein the ziprasidone metabolite is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, or orally.

11. (Original) The method of claim 10 wherein the ziprasidone metabolite is administered orally.

12. (Original) The method of claim 11 wherein the ziprasidone metabolite administered orally in a tablet or capsule form.

13. (Original) The method of claim 1 or 3 wherein the therapeutically effective amount of ziprasidone metabolite is between about 1 mg and about 1000 mg per day.

14. (Original) The method of claim 13 wherein the therapeutically effective amount of ziprasidone metabolite is between about 5 mg to about 500 mg per day.

15. (Original) The method of claim 14 wherein the therapeutically effective amount of ziprasidone metabolite is between about 10 mg to about 200 mg per day.

50. (Previously Added) A method of treating or prophylaxis of a neuroleptic disorder in a patient which comprises administering to a patient in need of such

treatment or prophylaxis a therapeutically effective amount of ziprasidone sulfoxide, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.

51. (Previously Added) The method of claim 50 wherein the neuroleptic disorder is psychosis, an affective disorder, or anxiety.

52. (Previously Added) A method of treating or prophylaxis of a neuroleptic disorder in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of ziprasidone sulfone, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.

53. (Previously Added) The method of claim 52 wherein the neuroleptic disorder is psychosis, an affective disorder, or anxiety.